ArticleThe Journal of infectious diseases2018
Cholera: Immunity and Prospects in Vaccine Development.
Article in The Journal of infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Long-Term Kinetics of Serological Antibodies againstInternational journal of environmental research and public health · 2022Pooled it
- Cholera for travellers.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Pre-vaccination biomarkers of enteric dysfunction, inflammation and nutritional status associate with seroconversion to oral cholera vaccine and are perturbed during natural infection.Frontiers in immunology · 2026Article
- Understanding cholera dynamics in African countries with persistent outbreaks: a mathematical modeling approach.BMC public health · 2025Article
- Impact of a multi-pronged cholera intervention in an endemic setting.PLoS neglected tropical diseases · 2025Article
- Biological threat preparedness through vaccine development and stockpiling: challenges and strategic implications.Frontiers in public health · 2025Review
- Article
- Cholera Outbreaks in Low- and Middle-Income Countries in the Last Decade: A Systematic Review and Meta-Analysis.Microorganisms · 2024Review
- Impact of a multi-pronged cholera intervention in an endemic setting.medRxiv : the preprint server for health sciences · 2024Article
- Article
- Vaccine Strategies to Elicit Mucosal Immunity.Vaccines · 2024Review
- The Vibrio cholerae maneuver.Trends in immunology · 2023Article
- Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines.ACS infectious diseases · 2023Review
- Review
- A polyvalent multiepitope protein cross-protects againstProceedings of the National Academy of Sciences of the United States of America · 2022Article
- InactivatedJournal of microbiology and biotechnology · 2022Article
- Enterotoxigenic Escherichia coli heat-labile toxin drives enteropathic changes in small intestinal epithelia.Nature communications · 2022Article
- Mucosal vaccines - fortifying the frontiers.Nature reviews. Immunology · 2022Review
- Virus-like Particle Display ofACS infectious diseases · 2022Article
- Animal models for dissecting Vibrio cholerae intestinal pathogenesis and immunity.Current opinion in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Vibrio cholerae is a prototypical noninvasive mucosal pathogen, yet infection generates long-lasting protection against subsequent disease. Vibriocidal antibody responses are an imperfect but established correlate of protection against cholera following both infection and vaccination. However, vibriocidal antibody responses are likely a surrogate marker for longer-lasting functional immune responses that target the O-polysaccharide antigen at the mucosal surface. While the current bivalent inactivated oral whole cell vaccine is being increasingly used to prevent cholera in areas where the disease is a threat, the most significant limitation of this vaccine is it offers relatively limited direct protection in young children. Future strategies for cholera vaccination include the development of cholera conjugate vaccines and the further development of live attenuated vaccines. Ultimately, the goal of a multivalent vaccine for cholera and other childhood enteric infections that can be incorporated into a standard immunization schedule should be realized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.